Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

Similar documents
Appendix K: Evidence review flow charts

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

Dr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care.

Appendix L: Research recommendations

Understanding Dementia

If you have dementia, you may have some or all of the following symptoms.

This information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.

Community Pharmacy Dementia Audit

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

Dementia Care Pathway

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

Understanding dementia

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Drug treatments for Alzheimer s disease

What is dementia? alzheimers.org.uk

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

NICE Quality Standards and commissioning dementia care

Dementia Alistair Burns National Clinical Director for Dementia

Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center

Medications for Alzheimer s disease: are they right for you?

Dementia and cognitive decline

Diagnosis and Treatment of Alzhiemer s Disease

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by

Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

From MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

Drugs used to relieve behavioural and psychological symptoms in dementia

Appendix 2017UEMS031

PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5

Managing Behavioural Problems in Patients with Learning Disabilities

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

DEMENTIA AND MEDICATION

Prescribing for people with dementia. Carol Paton Chief Pharmacist April 2009

Significance A Busy Clinician's Guide to Seniors with Memory Loss

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,

Resources: Types of dementia

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

Confusion in the acute setting Dr Susan Shenkin

Drugs for behavioural and psychological symptoms in dementia

If a bad thing is happening to a patient, a drug did it until proven otherwise

Clinical guideline Published: 22 November 2006 nice.org.uk/guidance/cg42

Fact Sheet Alzheimer s disease

Frequently Asked Questions About Dementia

Draft for Consultation

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

MOVEMENT DISORDERS AND DEMENTIA

Summary of Delirium Clinical Practice Guideline Recommendations Post Operative

Summary of funded Dementia Research Projects

The Basics of Alzheimer s Disease

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Rational Medication Use in Dementia

Dementia. Memory Evaluation Center Neurology

Appendix 2 (continued): Recommendations for the management of mild to moderate dementia, dementia with a cerebrovascular component, and for addressing

CLINICAL PRACTICE GUIDELINES AND PRINCIPLES OF CARE FOR PEOPLE WITH DEMENTIA

Dementia Diagnosis Guidelines Primary Care

Alzheimer s disease Treatment options

What is dementia? Symptoms. alzheimers.org.uk

Essential Shared Care Agreement Drugs for Dementia

Young onset dementia service Doncaster

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111)

A Palliative Approach in Caring for the Person and Family Living with Dementia Hospice and Palliative Nurses Association (HPNA) Online Education

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

Essential Shared Care Agreement Drugs for Dementia

Diagnosis and assessment

Memory Matters Service Dementia, Depression and Delerium Cancer Awareness Toolkit Evaluation Event

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA

DRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.

DEMENTIA DIAGNOSIS AND HEALTHCARE PATHWAY FOR PEOPLE WITH A LEARNING DISABILITY

Dr. Adeniyi Mofoluwake and Stacy Kramer

Neurocognitive Disorders Research to Emerging Therapies

Literature Scan: Alzheimer s Drugs

Medications for treating people with dementia: summary of evidence on cost-effectiveness

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

A report for the UK National Screening Committee

Alzheimer s disease. The facts in brief

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Session outline. Introduction to dementia Assessment of dementia Management of dementia Follow-up Review

Delirium Information for patients and relatives. Delirium is common Delirium is treatable Relatives can stay to help us

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

CEPP National Audit Antipsychotics in Dementia

Session outline. Introduction to depression Assessment of depression Management of depression Follow-up Review

Dementia Chronic Brain Failure The forgotten cardiovascular disease Clare Hawley 2015

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry

Next patient please Dementia Clare Hawley 2018

Transcription:

Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

How NICE guidelines are reviewed Multidisciplinary guideline committee established Review of research evidence If a lack of evidence is found recommendations for future research NOTE: wording is key when reading guidelines OFFER means a strong recommendation usually with clear evidence CONSIDER means recommendation where evidence less clear 2

Emphasis on Person-centred care Not changed and emphasised Remember these principles underpin planning and care Human value of individual person with dementia Individuality of person with dementia Importance of patient perspective Importance of carer and relationships for person with dementia Include people in decisions about them Provide accessible information

Advance Care Planning Offer early and ongoing opportunities for people to discuss planning ahead Including lasting power of attorney Advance statement of wishes Advance decision to refuse treatment Preferences around place of care and place of death

Initial Assessment of possible dementia Take history including from person and collateral information History of cognitive, behavioural and psychological symptoms If suspected dementia following steps Physical examination Appropriate blood tests and urine test to exclude reversible causes Cognitive test using validated brief structured cognitive instrument- eg 10- CS, 6CIT, 6 item screener, Memory Impairment Screen (MIS), Mini-Cog, Test your memory (TYM) Collateral history consider IQCODE (informant Q on cog decline eld)

Diagnosis in Specific Dementia Diagnostic Service Not our focus today but a few points to notice Refer MAS or similar, although neurology may be more appropriate at times New advice on testing for Alzheimer's if diagnosis not clear FDG-PET or Perfusion SPECT Lumbar puncture examining CSF for Tau, or amyloid beta 1-42 BUT: Exception not the rule. Dementia is a clinical diagnosis ultimately

Delirium versus Dementia If no diagnosis of dementia and unsure if delirium or dementia, consider using the following tools CAM the long confusion assessment method OSLA the observational scale of level of arousal Cognitive test is unhelpful to distinguish If unsure if dementia or delirium treat delirium first

Care Coordination People living with dementia should be provided with a single named health or social care professional who is responsible for coordinating their care Initial assessment of needs Provide information re services and how to access them Involve carer and family Consider those without capacity, and also difficult to reach groups Develop care and support plan (agreed with person, specified when reviewed, covers other health issues, copy with person and family, shared appropriately with other services with consent)

Interventions to promote cognition, independence and wellbeing Commissioners need to consider this Offer range of activities to promote wellbeing suitable for people with dementia Offer group CST (Cognitive Stimulation Therapy) Consider group reminiscence therapy Consider cognitive rehabilitation or occupational therapy to support functional ability Do not offer acupuncture, supplements (vit E, ginseng etc), brain stimulation, cognitive training

Pharmacological Interventions in Alzheimer's 3 acetylcholinesterase (AChE) inhibitors are used as monotherapy for mild to moderate alzhiemer s Donepezil, galantamine, rivastigmine If AChE inhibitor contraindicated or not tolerated in mild to moderate Alzheimer s use memantine as monotherapy In moderate severe Alzheimer s disease use memantine as monotherapy Prescribers should only start on advice of clinician with necessary knowledge and skills. (secondary care- psych, geriat, neurol or other health care professionals if they have specialist expertise).

Pharmacological Interventions in Alzheimer s part 2 Then Consider Memantine in addition to AChE inhibitors for moderate Alzheimer s Offer Memantine in addition to AChE inibitors for Severe Alzheimer s Don t stop AChE inhibitors because of severity of Alzheimer's disease alone If person is taking AChE inhib, primary care prescribers may start treatment with memantine without taking advice from specialist

Memantine NMDA receptor antagonist Blocks glutamate effects Glutamate released in increased amounts in Alzheimer s Can slow progression of symptoms disorientation May help with delusions, aggression, agitation Usually well tolerated (better tolerated than AChE inhibs) SE: dizziness, headaches, tiredness, elevated BP, constipation

Assessing Severity of Alzheimer's Don t rely on cognitive test score alone Consider physical, sensory or learning disabilities or communication difficulties can affect score results ICD 10 Research Definitions Moderate decline in cognitive abilities make the individual unable to function without assistance of another for daily living including shopping and handling money. Within the home, only simple chores can be performed. Activities are increasingly restricted Severe needs assistance with nearly all activities of daily living. People will need a significant package of care due to their level of cognitive impairment.

Non Alzheimer s dementia - pharmacological Dementia with lewy bodies donepezil or rivastigmine Vascular dementia only consider AChE inhib or memantine if comorbid Alzheimer s, Parkinson's disease dementia or dementia with lewy bodies Frontotemporal Dementia don t use AChE inhib or memantine

Medications causing cognitive impairment Consider anticholinergic burden Various tools available to review Medication reviews important Consider de-prescribing in elderly

Managing non Cognitive Symptoms Explore reasons for person s distress Try non pharmacological interventions Only antipsychotics if risk of harming self or others, or severe distress Use lowest dose for shortest possible time Reassess at 6 weeks and stop if no benefit Parkinson s disease dementia and dementia with lewy bodies antipsychotics may worsen motor features Consider sleep and pain Sensory impairments

Supporting Carers Offer psychoeducation and skills training Education about dementia and changes to expect in person with dementia Training to adapt communication styles for person with dementia Information of services available Advice on planning enjoyable and meaningful activities for the person with dementia Ensure support for carers if provided likely most effective in groups Advice on right to formal assessment of needs and assessment for respite